LONG-TERM EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT FOR CROHN’S DISEASE: RESULTS FROM THE VIVID-2 OPEN-LABEL EXTENSION STUDY

• Abstract

Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease

• Abstract
• Lay summary
• Supplementary data

Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis

• Abstract
• Lay summary
• Supplementary data

Risk of Paradoxical Rheumatoid Arthritis in Inflammatory Bowel Disease Patients Exposed to Tumor Necrosis Factor Inhibitors: A Propensity-Matched Multicenter Study

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study

• Abstract
• Lay summary
• Supplementary data

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

• Abstracts
• Lay summary

Postoperative Crohn’s Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection

• Abstract
• Lay summary
• Supplementary data

Correspondence on: Methodological Standards When Reporting From National Databases

• Extract

Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity

• Abstract
• Lay summary
• Supplementary data

BIOLOGICS AND SMALL MOLECULES USED IN IBD MIMICS: HIGHLIGHTING THE IMPORTANCE OF DIAGNOSIS CONFIRMATION

• Abstract

Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey

• Abstract
• Lay summary
• Supplementary data

Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus

• Abstract
• Supplementary data

Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies

• Abstract

Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?

Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection

• Abstract
• Lay summary
• Supplementary data

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program

• Abstract
• Lay summary
• Supplementary data

IBD MIMICS PRESENTED AT IBD LIVE: WHEN IT IS NOT INFLAMMATORY BOWEL DISEASE

• Abstract

Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn’s Disease

• Abstract
• Supplementary data

Ileocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance

• Abstract
• Supplementary data

Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease

• Abstract
• Supplementary data